Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Kuva Labs Inc. has commenced a tender offer to acquire all outstanding shares of Lisata Therapeutics (LSTA) for $4.00 per share in cash plus non-tradeable contingent value rights (CVRs). The CVRs provide potential additional upside of up to $3.00 per share, contingent on achieving specific clinical milestones: $1.25 for Phase 2a trial progress in glioblastoma and $1.75 for an NDA filing for certepetide. Lisata’s Board unanimously recommends the tender offer, which expires July 10, 2026.
Key figures
- Deal Value Usd
- $4.00 per share in cash plus CVRs
- Cvr max value
- 3
- Cash per share
- 4
- Expected closing
- Q3 2026
- Tender offer expiry
- July 10, 2026
- First milestone payment
- 1.25
- Second milestone payment
- 1.75
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.